Next 10 |
2024-05-09 16:04:01 ET More on Ventyx Biosciences Ventyx Pivots To Obesity Amid Transformation Ventyx Biosciences drops 3%, stockholders to sell ~11.17M shares Ventyx rebounds as Oppenheimer upgrades after pipeline updates Seeking Alpha’s Quant Rating ...
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as ...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ventyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 30, 2024) - Faruqi & Faruqi, LLP, a leading national se...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ventyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 29, 2024) - Faruqi & Faruqi, LLP, a leading national se...
Do you, or did you, own shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)? Did you purchase your shares pursuant and/or traceable to the Company's October 21, 2021 IPO, or between October 21, 2021 and November 6, 2023, inclusive? Did you lose money in your investment in Ventyx Biosciences,...
NEW YORK, April 22, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Ventyx Biosciences, Inc. (NASDAQ: VTYX)? Did you purchase your shares pursuant and/or traceable to the Company’s October 21, 2021 IPO, or between October 21, 2021 an...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ventyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 21, 2024) - Faruqi & Faruqi, LLP, a leading national se...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Ventyx To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - April 19, 2024) - Faruqi & Faruqi, LLP, a leading national se...
SAN DIEGO, April 17, 2024 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a deadline is coming up in the lawsuit that was filed for certain investors in Ventyx Biosciences, Inc. (NASDAQ: VTYX) shares. Investors, who purchased shares in excess of $100,000 of Ventyx Bioscie...
News, Short Squeeze, Breakout and More Instantly...
Ventyx Biosciences Inc. Company Name:
VTYX Stock Symbol:
NASDAQ Market:
Phase 2a trials of CNS-Penetrant NLRP3 Inhibitor VTX3232 to initiate in H2 2024 in patients with early Parkinson’s disease and in participants with obesity with certain additional cardiovascular risk factors Cash, cash equivalents and marketable securities of $302.6 million as ...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (NASDAQ:VTYX), ("Ventyx"), a clinical-stage biopharmaceutical company focus...
SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced th...